Draw attention to the teratogenic effect of DMD in MS treatment

Shi-Fang Hou, Yin Jian, Li-Yan Qiao, Zun-Bao Li, Kai Feng and Xian-Hao Xu*

More than 2.3 million people are affected by Multiple Sclerosis (MS) worldwide. Since the 1990s, disease modifying drug (DMD) has been developing increasingly. With more and more clinical applications, more and more attention has been paid to the adverse effects of DMD in the treatment of MS. DMD selection for patients with MS during pregnancy is one of the most important topics for neuroimmunologists and obstetrics. This comment is mainly based on our published and forthcoming data. 

Keywords:

Published on: Sep 18, 2020 Pages: 99-100

Full Text PDF Full Text HTML DOI: 10.17352/2455-1414.000081
CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos Universite de Paris UW Libraries SJSU King Library SJSU King Library NUS Library McGill DET KGL BIBLiOTEK JCU Discovery Universidad De Lima WorldCat VU on WorldCat